{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:44:51Z","timestamp":1792071891271,"version":"4.4.0"},"reference-count":23,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/ykzb8359","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T23:28:45Z","timestamp":1716766125000},"page":"2187-2201","source":"Crossref","is-referenced-by-count":3,"title":["The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer"],"prefix":"10.62347","volume":"14","author":[{"given":"Yun-Chieh","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1186\/s12885-020-07656-w","article-title":"Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis","volume":"20","author":"Rumpold","year":"2020","unstructured":"Rumpold H, Niedersüß-Beke D, Heiler C, Falch D, Wundsam HV, Metz-Gercek S, Piringer G and Thaler J. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer 2020; 20: 1149.","journal-title":"BMC Cancer"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"102218","DOI":"10.1016\/j.ctrv.2021.102218","article-title":"Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone","volume":"98","author":"Glimelius","year":"2021","unstructured":"Glimelius B, Stintzing S, Marshall J, Yoshino T and de Gramont A. Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev 2021; 98: 102218.","journal-title":"Cancer Treat Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_351354","article-title":"HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target","volume":"42","author":"Ahcene Djaballah","year":"2022","unstructured":"Ahcene Djaballah S, Daniel F, Milani A, Ricagno G and Lonardi S. HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target. Am Soc Clin Oncol Educ Book 2022; 42: 1-14.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H and Klempner SJ. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med 2023; 388: 44-54.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","article-title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","volume":"29","author":"Pietrantonio","year":"2018","unstructured":"Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F and Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol 2018; 29: 1394-1401.","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A and Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"RJ","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M and Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909-1919.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"GW","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L and Tabernero J; SUNLIGHT Investigators. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 2023; 388: 1657-1667.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"AE","year":"2023","unstructured":"Shin AE, Giancotti FG and Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci 2023; 44: 222-236.","journal-title":"Trends Pharmacol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014; 2014: 638747.","journal-title":"J Thyroid Res"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Iwasa S, Okita N, Kuchiba A, Ogawa G, Kawasaki M, Nakamura K, Shoji H, Honma Y, Takashima A, Kato K, Hamaguchi T, Boku N and Yamada Y. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). ESMO Open 2020; 5: e000776.","DOI":"10.1136\/esmoopen-2020-000776"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.esmoop.2023.101157","article-title":"Lenvatinib plus pembrolizumab a new effective combination of targeted agents","volume":"8","author":"Perez-Fidalgo","year":"2023","unstructured":"Perez-Fidalgo JA and Martinelli E. Lenvatinib plus pembrolizumab a new effective combination of targeted agents. ESMO Open 2023; 8: 101157.","journal-title":"ESMO Open"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Kawazoe A, Xu R, Passhak M, Teng H, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim T, Shiu K, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T and Élez E. LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study. Ann Oncol 2023; 34: S179.","DOI":"10.1016\/j.annonc.2023.04.015"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","unstructured":"Gu Z, Eils R and Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 2016; 32: 2847-2849.","journal-title":"Bioinformatics"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G and Noushmehr H. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 2016; 44: e71.","DOI":"10.1093\/nar\/gkv1507"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, Yamada K, Hori Y, Tabata K, Takase K, Matsui J, Funahashi Y and Nomoto K. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci 2018; 109: 3993-4002.","journal-title":"Cancer Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/JHC.S395474","article-title":"Synergistic effect of lenvatinib and chemotherapy in hepatocellular carcinoma using preclinical models","volume":"10","author":"Wang","year":"2023","unstructured":"Wang M, Yao X, Bo Z, Zheng J, Yu H, Xie X, Lin Z, Wang Y, Chen G and Wu L. Synergistic effect of lenvatinib and chemotherapy in hepatocellular carcinoma using preclinical models. J Hepatocell Carcinoma 2023; 10: 483-495.","journal-title":"J Hepatocell Carcinoma"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_349811","article-title":"Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues","volume":"42","author":"Sahin","year":"2022","unstructured":"Sahin IH, Ciombor KK, Diaz LA, Yu J and Kim R. Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues. Am Soc Clin Oncol Educ Book 2022; 42: 1-12.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Filleron T, Bachelier M, Mazieres J, Pérol M, Meyer N, Martin E, Mathevet F, Dauxois JY, Porcher R and Delord JP. Assessment of treatment effects and long-term benefits in immune checkpoint inhibitor trials using the flexible parametric cure model: a systematic review. JAMA Netw Open 2021; 4: e2139573.","DOI":"10.1001\/jamanetworkopen.2021.39573"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/DDDT.S85567","article-title":"Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study","volume":"9","author":"Suenaga","year":"2015","unstructured":"Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M and Yamaguchi T. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015; 9: 3099-3108.","journal-title":"Drug Des Devel Ther"},{"key":"ref20","unstructured":"Köstek O, Hacıoğlu MB, Sakin A, Demir T, Sarı M, Ozkul O, Araz M, Doğan AF, Demircan NC, Uzunoğlu S, Çiçin İ and Erdoğan B. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol 2019; 83: 115-122."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.3390\/cancers14225480","article-title":"A GNAS gene mutation’s independent expression in the growth of colorectal cancer: a systematic review and meta-analysis","volume":"14","author":"HA","year":"2022","unstructured":"Afolabi HA, Salleh SM, Zakaria Z, Ch’ng ES, Mohd Nafi SN, Abdul Aziz AAB, Irekeola AA, Wada Y and Al-Mhanna SB. A GNAS gene mutation’s independent expression in the growth of colorectal cancer: a systematic review and meta-analysis. Cancers (Basel) 2022; 14: 5480.","journal-title":"Cancers (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.neo.2014.09.008","article-title":"E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts","volume":"16","author":"Wiegering","year":"2014","unstructured":"Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergün S, Germer CT and Otto C. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. Neoplasia 2014; 16: 972-981.","journal-title":"Neoplasia"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/5\/ajcr0155958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:53:28Z","timestamp":1766022808000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/5\/ajcr0155958.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/ykzb8359","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}